martin owns 70% Of Shares & he is Not lending to Shorts- Common Sense this Will Only Continue to Squeeze Higher & Higher
buyer and holding
Investors should remember that Shkreli is now one of the most recognized faces for potential price gouging going into an election year.
was not forced at all, what are u talking about the captain left the ship and investors hanging.
Clovis Oncology (CLVS) has some explaining to do.
The Food and Drug Administration has requested more data on Clovis’ lead drug candidate rociletinib as it reviews the company’s new drug application, which will likely delay the drug’s approval, currently slated for March 30 of next year. More importantly, the updated results requested by FDA and released on Monday morning call into question rociletinib’s commercial potential, as the FDA just last week approved a similar, competing drug from AstraZeneca, with what now appears to be a superior efficacy profile.
Clovis Stumbles, AstraZeneca Leads Cancer Drug Race
BY AMY REEVES, INVESTOR'S BUSINESS DAILY
Cooperman's Omega no longer owns Valeant, CNBC reports »